Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VKTX – Viking Therapeutics Inc.

VKTX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

21.67

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

0.4

EPS Last/This Y

-0.85

EPS This/Next Y

-0.42

Price

33.72

Target Price

93.59

Analyst Recom

1.21

Performance Q

4.85

Upside

-222.7%

Beta

0.86

Ticker: VKTX



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09VKTX33.670.200.15152894
2026-03-10VKTX34.630.200.14157022
2026-03-11VKTX35.780.200.14161013
2026-03-12VKTX35.480.200.18163397
2026-03-13VKTX35.470.200.18163397
2026-03-17VKTX35.510.200.32158095
2026-03-18VKTX33.530.200.17159877
2026-03-19VKTX33.920.210.25161953
2026-03-20VKTX32.340.210.23162952
2026-03-23VKTX32.540.190.18144525
2026-03-24VKTX32.160.190.18150219
2026-03-25VKTX33.270.200.44151282
2026-03-26VKTX34.220.200.05154689
2026-03-27VKTX32.510.190.19159395
2026-03-30VKTX29.870.190.18152129
2026-03-31VKTX32.540.190.15153926
2026-04-01VKTX32.940.190.35159007
2026-04-02VKTX34.780.190.10163680
2026-04-06VKTX33.920.190.35159032
2026-04-07VKTX33.720.200.33162298
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09VKTX33.65-133.433.5-4.11
2026-03-10VKTX34.65-133.429.0-4.11
2026-03-11VKTX35.78-133.428.4-4.11
2026-03-12VKTX35.48-133.445.5-4.11
2026-03-13VKTX35.64-133.440.2-4.11
2026-03-17VKTX35.51-133.448.0-4.11
2026-03-18VKTX33.55-133.465.9-4.11
2026-03-19VKTX33.92-133.437.5-4.11
2026-03-20VKTX32.33-133.462.3-4.11
2026-03-23VKTX32.51-133.439.9-4.11
2026-03-24VKTX32.15-133.447.6-4.11
2026-03-25VKTX33.20-133.428.3-4.11
2026-03-26VKTX34.24-133.428.8-4.11
2026-03-27VKTX32.51-133.464.0-4.11
2026-03-30VKTX29.92-133.476.8-4.04
2026-03-31VKTX32.54-133.43.6-4.04
2026-04-01VKTX32.94-133.436.9-4.04
2026-04-02VKTX34.78-133.418.4-4.04
2026-04-06VKTX33.94-133.452.7-4.04
2026-04-07VKTX33.72-133.445.0-4.04
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09VKTX-12.22-1.1223.33
2026-03-10VKTX-12.22-1.1223.33
2026-03-11VKTX-12.12-1.1221.69
2026-03-12VKTX-12.12-1.1221.69
2026-03-13VKTX-12.12-1.1221.69
2026-03-17VKTX-12.12-1.1221.69
2026-03-18VKTX-12.12-1.1221.69
2026-03-19VKTX-12.12-1.1221.69
2026-03-20VKTX-12.12-1.1221.69
2026-03-23VKTX-12.12-1.1121.69
2026-03-24VKTX-12.12-1.1121.69
2026-03-25VKTX-12.12-1.1121.67
2026-03-26VKTX-12.12-1.1121.67
2026-03-27VKTX-12.12-1.1121.67
2026-03-30VKTX-12.12-1.1121.67
2026-03-31VKTX-12.12-1.1121.67
2026-04-01VKTX-12.12-1.1121.67
2026-04-02VKTX-12.12-1.1121.67
2026-04-06VKTX-12.12-1.1121.67
2026-04-07VKTX-12.12-1.1121.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-1.38

Avg. EPS Est. Current Quarter

-0.96

Avg. EPS Est. Next Quarter

-0.98

Insider Transactions

-12.12

Institutional Transactions

-1.11

Beta

0.86

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

18

Sentiment Score

93

Actual DrawDown %

66.1

Max Drawdown 5-Year %

-78.9

Target Price

93.59

P/E

Forward P/E

PEG

P/S

P/B

6.05

P/Free Cash Flow

EPS

-3.18

Average EPS Est. Cur. Y​

-4.04

EPS Next Y. (Est.)

-4.46

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.5

Return on Equity vs Sector %

-83.7

Return on Equity vs Industry %

-67.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

45
◆ VKTX Healthcare
$33.70
📉
Swing / Pullback
Buy the dip on strong trends
44 /100
WEAK
Trend
2/20
Pullback
15/25
Volume
8/15
Valuation
10/20
TP/AR
2/10
Options
7/10
RSI
52
Range 1M
46.9%
Sup Dist
0.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
20 /100
WEAK
Momentum
3/25
Growth
5/30
Estimates
0/20
Inst/Vol
2/15
Options
10/10
EPS Yr
-33.1%
EPS NY
-8.8%
52W%
60%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +177.7% upside
Quality
2/30
Valuation
15/30
Growth
1/25
Stability
7/10
LT Trend
2/5
Upside
+177.7%
Quality
9
Click a card to see score breakdown Full Analysis →
Viking Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 53
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX

Latest News

—
Caricamento notizie per VKTX…
stock quote shares VKTX – Viking Therapeutics Inc. Stock Price stock today
news today VKTX – Viking Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading

VKTX – Viking Therapeutics, Inc.

VKTX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

21.67

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

0.4

EPS Last/This Y

-0.85

EPS This/Next Y

-0.42

Price

33.72

Target Price

93.59

Analyst Recom

1.21

Performance Q

4.85

Upside

-222.7%

Beta

0.86

Ticker: VKTX



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09VKTX33.670.200.15152894
2026-03-10VKTX34.630.200.14157022
2026-03-11VKTX35.780.200.14161013
2026-03-12VKTX35.480.200.18163397
2026-03-13VKTX35.470.200.18163397
2026-03-17VKTX35.510.200.32158095
2026-03-18VKTX33.530.200.17159877
2026-03-19VKTX33.920.210.25161953
2026-03-20VKTX32.340.210.23162952
2026-03-23VKTX32.540.190.18144525
2026-03-24VKTX32.160.190.18150219
2026-03-25VKTX33.270.200.44151282
2026-03-26VKTX34.220.200.05154689
2026-03-27VKTX32.510.190.19159395
2026-03-30VKTX29.870.190.18152129
2026-03-31VKTX32.540.190.15153926
2026-04-01VKTX32.940.190.35159007
2026-04-02VKTX34.780.190.10163680
2026-04-06VKTX33.920.190.35159032
2026-04-07VKTX33.720.200.33162298
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09VKTX33.65-133.433.5-4.11
2026-03-10VKTX34.65-133.429.0-4.11
2026-03-11VKTX35.78-133.428.4-4.11
2026-03-12VKTX35.48-133.445.5-4.11
2026-03-13VKTX35.64-133.440.2-4.11
2026-03-17VKTX35.51-133.448.0-4.11
2026-03-18VKTX33.55-133.465.9-4.11
2026-03-19VKTX33.92-133.437.5-4.11
2026-03-20VKTX32.33-133.462.3-4.11
2026-03-23VKTX32.51-133.439.9-4.11
2026-03-24VKTX32.15-133.447.6-4.11
2026-03-25VKTX33.20-133.428.3-4.11
2026-03-26VKTX34.24-133.428.8-4.11
2026-03-27VKTX32.51-133.464.0-4.11
2026-03-30VKTX29.92-133.476.8-4.04
2026-03-31VKTX32.54-133.43.6-4.04
2026-04-01VKTX32.94-133.436.9-4.04
2026-04-02VKTX34.78-133.418.4-4.04
2026-04-06VKTX33.94-133.452.7-4.04
2026-04-07VKTX33.72-133.445.0-4.04
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09VKTX-12.22-1.1223.33
2026-03-10VKTX-12.22-1.1223.33
2026-03-11VKTX-12.12-1.1221.69
2026-03-12VKTX-12.12-1.1221.69
2026-03-13VKTX-12.12-1.1221.69
2026-03-17VKTX-12.12-1.1221.69
2026-03-18VKTX-12.12-1.1221.69
2026-03-19VKTX-12.12-1.1221.69
2026-03-20VKTX-12.12-1.1221.69
2026-03-23VKTX-12.12-1.1121.69
2026-03-24VKTX-12.12-1.1121.69
2026-03-25VKTX-12.12-1.1121.67
2026-03-26VKTX-12.12-1.1121.67
2026-03-27VKTX-12.12-1.1121.67
2026-03-30VKTX-12.12-1.1121.67
2026-03-31VKTX-12.12-1.1121.67
2026-04-01VKTX-12.12-1.1121.67
2026-04-02VKTX-12.12-1.1121.67
2026-04-06VKTX-12.12-1.1121.67
2026-04-07VKTX-12.12-1.1121.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-1.38

Avg. EPS Est. Current Quarter

-0.96

Avg. EPS Est. Next Quarter

-0.98

Insider Transactions

-12.12

Institutional Transactions

-1.11

Beta

0.86

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

18

Sentiment Score

93

Actual DrawDown %

66.1

Max Drawdown 5-Year %

-78.9

Target Price

93.59

P/E

Forward P/E

PEG

P/S

P/B

6.05

P/Free Cash Flow

EPS

-3.18

Average EPS Est. Cur. Y​

-4.04

EPS Next Y. (Est.)

-4.46

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.5

Return on Equity vs Sector %

-83.7

Return on Equity vs Industry %

-67.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

45
◆ VKTX Healthcare
$33.70
📉
Swing / Pullback
Buy the dip on strong trends
44 /100
WEAK
Trend
2/20
Pullback
15/25
Volume
8/15
Valuation
10/20
TP/AR
2/10
Options
7/10
RSI
52
Range 1M
46.9%
Sup Dist
0.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
20 /100
WEAK
Momentum
3/25
Growth
5/30
Estimates
0/20
Inst/Vol
2/15
Options
10/10
EPS Yr
-33.1%
EPS NY
-8.8%
52W%
60%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +177.7% upside
Quality
2/30
Valuation
15/30
Growth
1/25
Stability
7/10
LT Trend
2/5
Upside
+177.7%
Quality
9
Click a card to see score breakdown Full Analysis →
Viking Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 53
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX

Latest News

—
Caricamento notizie per VKTX…
stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today
news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics, Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading